Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

See Locations Near You

Summary

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also evaluate the anti-tumor activity of IPI-504.

View Full Description

Full Description

IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in maintaining the proper folding, function and viability of various "client proteins". Many of the client proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. This clinical trial will study the effects of IPI-504 in a molecularly defined sub-group of patients who carry client proteins found in non-small cell lung cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or pericardial effusion) or Stage IV NSCLC
Measurable disease by RECIST criteria.

Exclusion Criteria:

Treatment for NSCLC with any approved or investigational product within 2 weeks of the start of IPI-504 treatment for any small molecule therapy; within 4 weeks of the start of IPI-504 treatment for any biologic or any conventional chemotherapy.
Inadequate hematologic or renal or hepatic function
Previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

88

Study ID:

NCT00431015

Recruitment Status:

Completed

Sponsor:

Infinity Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Cedars-Sinai Medical Center
Los Angeles California, 90048, United States
Yale Comprehensive Cancer Center
New Haven Connecticut, 06519, United States
Mount Sinai Comprehensive Cancer Center
Miami Florida, 33140, United States
H. Lee Moffitt Cancer Center
Tampa Florida, 33612, United States
Medical College of Georgia
Augusta Georgia, 30912, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02115, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Mary Crowley Cancer Research Centers - Medical City
Dallas Texas, 75201, United States
Mary Crowley Cancer Research Centers - Baylor
Dallas Texas, 75246, United States
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

88

Study ID:

NCT00431015

Recruitment Status:

Completed

Sponsor:


Infinity Pharmaceuticals, Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider